Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perls' Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC).
Lours C, Cottin L, Wiber M, Andrieu V, Baccini V, Baseggio L, Brouzes C, Chatelain B, Daliphard S, Fenneteau O, Geneviève F, Girard S, Leymarie V, Maloum K, Rieu JB, Sebahoun G, Sudaka I, Troussard X, Wagner-Ballon O, Wuilleme S, Bardet V, Lesesve JF. Lours C, et al. Among authors: girard s. Diagnostics (Basel). 2022 Jul 12;12(7):1698. doi: 10.3390/diagnostics12071698. Diagnostics (Basel). 2022. PMID: 35885602 Free PMC article.
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.
Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, Giroux C, Hernandez L, Kabongo E, Savola S, Leblanc T, Yakouben K, Plat G, Costa V, Ferster A, Girard S, Fenneteau O, Cayuela JM, Sigaux F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Soulier J, Cavé H. Clappier E, et al. Among authors: girard s. Leukemia. 2014 Jan;28(1):70-7. doi: 10.1038/leu.2013.277. Epub 2013 Sep 25. Leukemia. 2014. PMID: 24064621
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G, Kaltenbach S, Yakouben K, Mazingue F, Robert A, Boutard P, Plantaz D, Rohrlich P, van Vlierberghe P, Preudhomme C, Otten J, Speleman F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H; EORTC-CLG. Clappier E, et al. Among authors: girard s. Leukemia. 2010 Dec;24(12):2023-31. doi: 10.1038/leu.2010.205. Epub 2010 Sep 23. Leukemia. 2010. PMID: 20861920 Clinical Trial.
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M, Plesa A, Girard S, Marceau-Renaut A, Renard C, Bertrand Y. Penel-Page M, et al. Among authors: girard s. Pediatr Blood Cancer. 2020 Jun;67(6):e28305. doi: 10.1002/pbc.28305. Epub 2020 Apr 19. Pediatr Blood Cancer. 2020. PMID: 32307866 Clinical Trial.
420 results